Harold C. Simmons Comprehensive Cancer Center, UT Southwestern
North Texas's NCI comprehensive centre, where the HIF-2 inhibitor belzutifan, stereotactic body radiotherapy and the cGAS-STING pathway were born.
NCI-designated in 2010 and comprehensive since 2015, Simmons is the only NCI comprehensive centre in North Texas and is directed by breast oncologist Carlos Arteaga. James Brugarolas's kidney cancer programme and the UTSW spin-out Peloton Therapeutics produced the HIF-2 alpha inhibitor belzutifan, acquired by Merck in 2019 and approved for VHL disease and renal cell carcinoma. Robert Timmerman pioneered stereotactic body radiotherapy for lung and other tumours, and Zhijian 'James' Chen discovered the cGAS-STING innate immune sensing pathway that STING agonists exploit. Ralph DeBerardinis's cancer metabolism work at Children's Medical Center Research Institute adds a strong basic science programme.
- Kidney cancer and HIF-2
- Stereotactic body radiotherapy
- Innate immunity (cGAS-STING)
- Cancer metabolism
Pages like this
not linked directly; found by shared links- TrialLITESPARK-022
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- TrialLITESPARK-005
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- PersonWilliam G. Kaelin Jr.
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- TermVon Hippel-Lindau disease
Shares Belzutifan, HIF-2α, Renal cell carcinoma.
- TermOligoprogression
Shares Oligometastatic disease, SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer.
- IdeaReprogramme the liver's own immune cells to refuse metastases
Shares STING & innate immune agonists, Oligometastatic disease.
- TrialLITESPARK-012
Shares Belzutifan, Renal cell carcinoma.
- IdeaBiopsy the one lesion that is growing while the others shrink
Shares Oligometastatic disease, SBRT / SABR (stereotactic radiotherapy), Non-small-cell lung cancer.